Neuronetics Reports Third Quarter 2026 Financial and Operating Results

MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the third quarter of 2026.

Third Quarter 2026 Highlights * Total revenue increased 12.5% year-over-year to $42.0 million * Greenbrook revenue increased 20.1% year-over-year to $26.2 million * Adjusted EBITDA of $1.9 million compared to $(4.7) million in the third quarter of 2025 * Net loss of $1.6 million compared to a loss of $9.4 million in the third quarter of 2025 * Cash provided by operating and investing of $0.8 million compared to $(0.9) million in the third quarter of 2025 Recent Operational Highlights * Submitted 510(k) application for accelerated TMS * Entered agreement with Wave Neuro to pursue treatment of PTSD pending 510(k) submission * NeuroStar Launched First-Ever TMS Integration with EHR/EMR Platform “This quarter showed our strategy taking hold across our business. We delivered a record third quarter within Greenbrook as well as NeuroStar system sales. This reflects both our revenue cycle management advances as well as the positive reception of our expanded NeuroStar go-to-market options. We also continued to demonstrate our prioritization on profitability and cashflow generation,” said Dan Reuvers, President and Chief Executive Officer of Neuronetics. “We’re continuing to focus on new and expanded partnerships for NeuroStar, serving more patients in our Greenbrook clinics and preparing for the introduction of an even more comprehensive offering with the introduction of psychedelics.”